A Phase I/II Pilot Treatment Study Of CSF Penetration And Response To Ganciclovir And Foscarnet In CMV Neurologic Disease.

NCT00000856 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

NIH

Sponsor class

Conditions

Encephalopathy
HIV Infections
Radiculitis

Interventions

DRUG: Foscarnet sodium
DRUG: Ganciclovir

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)